Bailey William C, Tashkin Donald P
University of Alabama Lung Health Center, University of Alabama at Birmingham, 620 South 20th Street, Suite NHB 104, Birmingham, AL 35249-7337, USA.
Proc Am Thorac Soc. 2007 Oct 1;4(7):543-8. doi: 10.1513/pats.200701-017FM.
Chronic obstructive pulmonary disease (COPD) is increasing in the United States and throughout the world. There have been a number of advances in the treatment of this disease within the last several decades, and these improved therapies continue to become available, making the prospects for the future encouraging. Bronchodilation is the treatment of choice, and we point out in this article the potential availability of many new bronchodilators. There will be several options in the beta(2)-agonist and the anticholinergic categories for once-a-day preparations. There will also be a number of products combining these categories of bronchodilators and inhaled steroids, and the combination products will be available in once-a-day preparations. Also under development are several candidates for specific and effective antiinflammatory agents in COPD. It is likely that our ability to control the inflammation underlying COPD will be a reality in the future. Although many new cases of COPD are being diagnosed in former smokers, for patients who smoke, the most important treatment is smoking cessation. A number of new drugs are available, and more will be brought to market in the future. We have highlighted the details of this important area.
慢性阻塞性肺疾病（COPD）在美国及全球范围内都呈上升趋势。在过去几十年里，这种疾病的治疗取得了诸多进展，并且这些改进后的疗法不断涌现，使得未来前景令人鼓舞。支气管扩张是首选治疗方法，我们在本文中指出了许多新型支气管扩张剂的潜在可用性。在β₂受体激动剂和抗胆碱能药物类别中，将会有多种一日一次制剂可供选择。还会有许多将这些类别的支气管扩张剂与吸入性类固醇相结合的产品，且这些联合产品也将有一日一次制剂。此外，针对COPD的特异性和有效抗炎药物的几种候选药物也正在研发中。未来我们控制COPD潜在炎症的能力很可能会成为现实。尽管许多COPD新病例是在既往吸烟者中被诊断出来的，但对于吸烟的患者来说，最重要的治疗方法是戒烟。现在有多种新药可供使用，未来还会有更多药物上市。我们已经突出了这一重要领域的细节。
